Anti-IL17A autoantibodies for treating or reducing the likelihood of occurrence of bone destruction associated with a chronic autoimmune or inflammatory disease
AssigneesHospices Civil De Lyon, Universite Claude Bernard Lyon 1, Eurobio Scientific
InventorsPierre Miossec, Ndieme Thiam, Jean-Jacques Pin
Life of this patent
Estimating the term…
Abstract
The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoantibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.
Claims5
An in vitro method for isolating an anti-IL-17A autoantibody or a cell producing the autoantibody comprising:
- a) selecting an individual with a non-destructive rheumatoid arthritis;
- b) detecting an anti-IL-17A autoantibody and/or an IL-17A/anti-IL-17A autoantibody complex, or a cell producing the autoantibody in a biological sample from the individual;
- and
- c) isolating the anti-IL-17A autoantibody or the cell producing the autoantibody from the biological sample of the individual.
Dependencies are inferred from the claim text.